Coloplast A/S (CLPBY) To Go Ex-Dividend on May 16th

Coloplast A/S (OTCMKTS:CLPBY) declared a dividend on Friday, May 16th, investing.com reports. Shareholders of record on Monday, May 19th will be given a dividend of 0.0389 per share on Thursday, May 22nd. This represents a yield of 2.02%. The ex-dividend date of this dividend is Friday, May 16th.

Coloplast A/S Price Performance

OTCMKTS CLPBY opened at $9.60 on Friday. The company has a quick ratio of 0.66, a current ratio of 1.02 and a debt-to-equity ratio of 0.92. The company has a fifty day moving average of $10.39 and a two-hundred day moving average of $11.17. Coloplast A/S has a 52 week low of $9.43 and a 52 week high of $14.14.

Coloplast A/S (OTCMKTS:CLPBY) last issued its earnings results on Tuesday, May 6th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The company had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $7.02 billion. Coloplast A/S had a net margin of 17.81% and a return on equity of 28.60%. As a group, equities analysts predict that Coloplast A/S will post 0.31 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CLPBY. Sanford C. Bernstein raised shares of Coloplast A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 28th. Barclays lowered shares of Coloplast A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 7th. Finally, Royal Bank of Canada lowered shares of Coloplast A/S from a “moderate buy” rating to a “hold” rating in a research note on Friday, May 9th. Four equities research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold”.

Coloplast A/S Company Profile

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.